166 related articles for article (PubMed ID: 24308640)
1. Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2.
Brouwers MC; van Greevenbroek MM; Konrad RJ; Troutt JS; Schaper NC; Stehouwer CD
Clin Sci (Lond); 2014 May; 126(9):679-84. PubMed ID: 24308640
[TBL] [Abstract][Full Text] [Related]
2. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
3. Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia.
Brouwers MC; van Greevenbroek MM; Troutt JS; Bonner Freeman A; Lu A; Schaper NC; Konrad RJ; Stehouwer CD
Clin Sci (Lond); 2011 Nov; 121(9):397-403. PubMed ID: 21539517
[TBL] [Abstract][Full Text] [Related]
4. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
[TBL] [Abstract][Full Text] [Related]
5. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
Brouwers MC; Troutt JS; van Greevenbroek MM; Ferreira I; Feskens EJ; van der Kallen CJ; Schaper NC; Schalkwijk CG; Konrad RJ; Stehouwer CD
Atherosclerosis; 2011 Jul; 217(1):263-7. PubMed ID: 21497351
[TBL] [Abstract][Full Text] [Related]
6. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
7. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
Constantinides A; Kappelle PJ; Lambert G; Dullaart RP
Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
[TBL] [Abstract][Full Text] [Related]
8. Parabolic relationship between plasma triacylglycerols and LDL-cholesterol in familial combined hyperlipidaemia: the multiple-type hyperlipidaemia explained?
Brouwers MC; de Graaf J; van Greevenbroek MM; Georgieva AM; van der Kallen CJ; Ter Avest E; Stehouwer CD; Stalenhoef AF; de Bruin TW
Clin Sci (Lond); 2008 Mar; 114(5):393-401. PubMed ID: 17953518
[TBL] [Abstract][Full Text] [Related]
9. A PCSK9 variant and familial combined hyperlipidaemia.
Abifadel M; Bernier L; Dubuc G; Nuel G; Rabès JP; Bonneau J; Marques A; Marduel M; Devillers M; Munnich A; Erlich D; Varret M; Roy M; Davignon J; Boileau C
J Med Genet; 2008 Dec; 45(12):780-6. PubMed ID: 18708425
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
11. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
Jin K; Park BS; Kim YW; Vaziri ND
Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
Saavedra YG; Dufour R; Davignon J; Baass A
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
[TBL] [Abstract][Full Text] [Related]
13. Common and low-frequency genetic variants in the PCSK9 locus influence circulating PCSK9 levels.
Chernogubova E; Strawbridge R; Mahdessian H; Mälarstig A; Krapivner S; Gigante B; Hellénius ML; de Faire U; Franco-Cereceda A; Syvänen AC; Troutt JS; Konrad RJ; Eriksson P; Hamsten A; van 't Hooft FM
Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1526-34. PubMed ID: 22460556
[TBL] [Abstract][Full Text] [Related]
14. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
Kwakernaak AJ; Lambert G; Dullaart RP
Clin Biochem; 2012 Nov; 45(16-17):1522-4. PubMed ID: 22809551
[TBL] [Abstract][Full Text] [Related]
15. Docosahexaenoic Acid Attenuates Cardiovascular Risk Factors via a Decline in Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Plasma Levels.
Rodríguez-Pérez C; Ramprasath VR; Pu S; Sabra A; Quirantes-Piné R; Segura-Carretero A; Jones PJ
Lipids; 2016 Jan; 51(1):75-83. PubMed ID: 26620373
[TBL] [Abstract][Full Text] [Related]
16. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
[TBL] [Abstract][Full Text] [Related]
17. A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.
Gauthier MS; Pérusse JR; Awan Z; Bouchard A; Tessier S; Champagne J; Krastins B; Byram G; Chabot K; Garneau P; Rabasa-Lhoret R; Faubert D; Lopez MF; Seidah NG; Coulombe B
Methods; 2015 Jun; 81():66-73. PubMed ID: 25770357
[TBL] [Abstract][Full Text] [Related]
18. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
[TBL] [Abstract][Full Text] [Related]
19. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
20. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients.
Kappelle PJ; Lambert G; Dullaart RP
Atherosclerosis; 2011 Feb; 214(2):432-5. PubMed ID: 21122860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
